Sakar Healthcare Limited

Sakar Healthcare Limited, established on March 26, 2004, is a public limited company headquartered in Ahmedabad, Gujarat, India. The company specializes in the research, development, manufacturing, and marketing of a diverse range of pharmaceutical formulations, including liquid orals, cephalosporin tablets, capsules, dry powder syrups, injections, and lyophilized injections. Its product portfolio spans various therapeutic areas such as anti-infective, analgesic, antihistamine, anthelmintic, anti-malarial, antibacterial, vitamins, antifungal, diuretics, oxytocic, antacid, laxative, anticoagulant, anaesthetic, bronchodilator, adrenergic, sedative, anti-inflammatory, antiemetic, anticonvulsant, antipsychotic, antidepressant, and anti-cancer.

The company is listed on the National Stock Exchange of India under the ticker symbol SAKAR. As of January 1, 2026, Sakar Healthcare Limited has a market capitalization of approximately ₹8.92 billion (INR), equivalent to about $99.2 million USD. In the fiscal year ending March 31, 2025, the company reported a revenue of ₹1.78 billion, marking a 15.53% increase from the previous year. The workforce comprises approximately 342 employees.

Sakar Healthcare Limited operates multiple state-of-the-art manufacturing facilities in Changodar, Ahmedabad, Gujarat. These facilities are equipped to produce a wide array of pharmaceutical products, including liquid orals, cephalosporin tablets, capsules, dry powder syrups, injections, and lyophilized injections. The company's liquid and lyophilized injection unit (small volume parenterals in ampoules and vials) has been approved by the European Union's Good Manufacturing Practice (EU GMP), ensuring adherence to stringent quality standards. Additionally, all manufacturing units are certified by ISO 9001:2015 (BVQI), WHO-GMP, cGMP, and have approvals from national drug authorities in countries such as Uganda, Kenya, Yemen, Ethiopia, Congo, Ghana, Zimbabwe, Cambodia, Vietnam, Malawi, Namibia, Nigeria, Côte d'Ivoire, Philippines, and Peru.

Sakar Healthcare Limited is led by a team of experienced professionals committed to the company's growth and success. The key executives include:

• Sanjay Surendra Shah: Chairman and Managing Director
• Aarsh Sanjay Shah: Joint Managing Director
• Rita Shah: Whole-Time Director
• Sunil Vasantrao Marathe: Technical Director and Whole-Time Director
• Dharmesh R. Thaker: Chief Financial Officer
• Sudhir Ghuleas: Chief Operating Officer
• Raviraj Kariaas: Senior Vice President of Finance and Accounts
• Bharat Sukhlal Soni: Company Secretary and Compliance Officer
• Nimesh Suthar: Senior Vice President of International Business

This leadership team is dedicated to steering Sakar Healthcare Limited towards continued success and expansion in the pharmaceutical industry.

Sakar Healthcare Limited has made significant strides in establishing a presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities hold EU GMP certification, which is a prerequisite for marketing pharmaceutical products in the European Union. This certification underscores the company's commitment to maintaining high-quality manufacturing standards.

In the United States, Sakar Healthcare Limited has been proactive in seeking regulatory approvals. The company has filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) for various products, aiming to enter the U.S. generic pharmaceutical market. While specific approval statuses are not detailed in the available sources, the company's efforts indicate a strategic focus on expanding its footprint in the U.S. market.

The company's adherence to international quality standards and its proactive approach to obtaining necessary certifications and approvals reflect its commitment to meeting the stringent requirements of these regulated markets.

Sakar Healthcare Limited has strategically expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's products are exported to countries in these regions, including Uganda, Kenya, Yemen, Ethiopia, Congo, Ghana, Zimbabwe, Cambodia, Vietnam, Malawi, Namibia, Nigeria, Côte d'Ivoire, Philippines, and Peru.

The World Health Organization (WHO) prequalification of Sakar Healthcare's manufacturing facilities has facilitated access to these markets. WHO prequalification is a rigorous process that assesses the quality, safety, and efficacy of pharmaceutical products, enabling manufacturers to supply medicines to UN agencies and other international organizations. By obtaining WHO prequalification, Sakar Healthcare Limited has enhanced its credibility and competitiveness in these emerging markets.

Sakar Healthcare Limited's geographic strategy demonstrates a balanced approach to market diversification. The company's export activities span Southeast Asia, Africa, the Middle East and North Africa (MENA) region, and the United States, indicating a broad international presence.

This diversification strategy mitigates concentration risk by reducing dependence on any single market. The company's focus on obtaining international certifications, such as EU GMP and WHO prequalification, further supports its strategic direction to access and expand in regulated and emerging markets.

Sakar Healthcare Limited has been active in seeking approvals from the U.S. Food and Drug Administration (FDA) to market its pharmaceutical products in the United States. The company has filed Abbreviated New Drug Applications (ANDAs) for various products, aiming to enter the U.S. generic pharmaceutical market. While specific approval statuses are not detailed in the available sources, the company's proactive approach indicates a strategic focus on expanding its footprint in the U.S. market.

The company's efforts to obtain FDA approvals reflect its commitment to adhering to international quality standards and regulatory requirements, positioning it to compete effectively in the U.S. pharmaceutical market.

Sakar Healthcare Limited's manufacturing facilities are certified by the World Health Organization's Good Manufacturing Practice (WHO-GMP) and the European Union's Good Manufacturing Practice (EU GMP). These certifications are indicative of the company's adherence to stringent international quality standards in pharmaceutical manufacturing.

The EU GMP certification, in particular, is crucial for marketing pharmaceutical products within the European Union, reflecting the company's commitment to maintaining high-quality manufacturing standards.

In India, Sakar Healthcare Limited operates under the regulatory framework established by the Central Drugs Standard Control Organisation (CDSCO). The company's manufacturing units are certified by WHO-GMP, cGMP, and have approvals from national drug authorities in various countries, including Uganda, Kenya, Yemen, Ethiopia, Congo, Ghana, Zimbabwe, Cambodia, Vietnam, Malawi, Namibia, Nigeria, Côte d'Ivoire, Philippines, and Peru.

These certifications and approvals demonstrate the company's compliance with both domestic and international regulatory standards, ensuring the quality and safety of its pharmaceutical products.

As of March 28, 2026, there are no publicly available records indicating that Sakar Healthcare Limited has received any Form 483 observations, warning letters, or import alerts from regulatory authorities such as the U.S. Food and Drug Administration (FDA). This absence suggests that the company maintains a positive compliance record with regulatory agencies.

Sakar Healthcare Limited operates in a competitive pharmaceutical industry, facing competition from both domestic and international companies. While specific competitors are not detailed in the available sources, the company's focus on obtaining international certifications, such as EU GMP and WHO prequalification, positions it to compete effectively in regulated markets.

Sakar Healthcare Limited's key differentiators include its comprehensive product portfolio covering a wide range of therapeutic areas, its adherence to international quality standards evidenced by certifications like EU GMP and WHO-GMP, and its strategic focus on expanding into both regulated and emerging markets.

Sakar Healthcare Limited's current strategic direction emphasizes the expansion of its product offerings and market presence.